Related references
Note: Only part of the references are listed.Adding pharmacogenetics information to drug labels: lessons learned
Susanne B. Haga et al.
PHARMACOGENETICS AND GENOMICS (2006)
Novel personalized medicine technology:: UGT1A1 testing for irinotecan as a case study
Stephanie L. Van Bebber et al.
PERSONALIZED MEDICINE (2006)
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer
Kazuhiro Araki et al.
CANCER SCIENCE (2006)
UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females
J. Mercke Odeberg et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Genetic Variability, Haplotypes, and htSNPs for Exons 1 at the Human UGT1A Locus
Sushma S. Thomas et al.
HUMAN MUTATION (2006)
Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin
Ji-Youn Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a dutch population
T. M. Bosch et al.
MOLECULAR DIAGNOSIS & THERAPY (2006)
Link between colorectal cancer and polymorphisms in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes
Kung-Sheng Tang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S)
S Krishnaswamy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes
F Innocenti et al.
PHARMACOGENETICS AND GENOMICS (2005)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer
K Sai et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity
H Yamanaka et al.
PHARMACOGENETICS (2004)
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
A Font et al.
INVESTIGATIONAL NEW DRUGS (2003)
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
F Innocenti et al.
PHARMACOGENETICS (2002)
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients
M Ando et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia
J Sugatani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus:: functional consequences of three novel missense mutations in the human UGT1A7 gene
C Guillemette et al.
PHARMACOGENETICS (2000)
Share Paper
